Spruce Biosciences Inc at SVB Securities Global Biopharma Conference (Virtual) Transcript
Hello. Welcome to this presentation with Spruce Biosciences. We're pleased to have Javier Szwarcberg with us today to walk us through the story, provide an update, and then we'll have some Q&A at the end. Thanks so much for being with us, Javier.
Thank you so much, Joe. Much appreciated. So let me start with my presentation here. Through the course of my presentation, I'll be making some forward-looking statements. So I urge you to review prior releases, prior filings that we've made along the way.
So to start, CAH is a fairly large disease, is a $3 billion market opportunity for us. It has low competitive intensity, and a disease that hasn't seen a lot of new therapeutic options in 50 years. With the advent of steroids in the late 50s, early 60s, initially, there were -- frankly, quite transforming, right?
But patients need to take steroids in the context of supply and what's missing, what the body can't make. But in the context of CAH, they
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |